Chemotherapy for Neuroendocrine Carcinoma of the Larynx
For poorly differentiated neuroendocrine carcinoma of the larynx, treat with platinum-etoposide chemotherapy following small cell lung cancer regimens: either cisplatin 100 mg/m² plus etoposide or carboplatin plus etoposide, typically combined with radiotherapy in a multimodal approach.
Treatment Algorithm Based on Tumor Grade
High-Grade (Poorly Differentiated) Neuroendocrine Carcinoma
The NCCN guidelines explicitly state that poorly differentiated neuroendocrine tumors should be treated following small cell lung cancer regimens 1. This is the cornerstone recommendation.
First-line chemotherapy options:
- Cisplatin 100 mg/m² plus etoposide (preferred) 1
- Carboplatin plus etoposide (equally effective alternative, particularly for elderly or poor-risk patients) 1
- Response rate: 73% for both regimens
- Median overall survival: 10.6 months (carboplatin/etoposide) vs 9.9 months (cisplatin/etoposide) - no significant difference 1
Alternative regimen for metastatic disease:
- Paclitaxel, carboplatin, and etoposide showed major responses in 53% of patients with poorly differentiated neuroendocrine carcinomas, with median survival of 14.5 months and 2-year survival of 33% 1
Low-Grade (Well-Differentiated) Neuroendocrine Tumors
For lower-grade tumors, the approach differs significantly:
- Somatostatin analogs (octreotide LAR) for functional tumors 2
- Temozolomide alone or with capecitabine has shown clinical benefit 1, 2
- Everolimus (mTOR inhibitor) demonstrated clear benefit in neuroendocrine tumors 2
Multimodal Treatment Strategy
The evidence strongly supports combining chemotherapy with other modalities:
Surgery + adjuvant chemoradiotherapy is the most appropriate approach when feasible 3, 4, 5
Sequential chemoradiotherapy for unresectable disease 6
- Cisplatin/etoposide followed by radiotherapy shows good initial response 6
Concurrent chemoradiotherapy for locally advanced disease
- Cisplatin 100 mg/m² on days 1,22, and 43 with concurrent radiotherapy (70 Gy) is the standard for head and neck cancers 7
Critical Clinical Considerations
Tumor behavior and prognosis:
- Neuroendocrine carcinomas of the larynx are extremely aggressive with high recurrence rates 6, 3, 4
- Clinical behavior depends heavily on tumor grade and differentiation 1
- Despite aggressive treatment, recurrence often occurs within one year 6
Common pitfall: Do not treat laryngeal neuroendocrine carcinoma like typical non-small cell lung cancer. Research demonstrates that SCLC-type regimens (platinum/etoposide) are more appropriate than NSCLC regimens, with better overall survival (16.5 vs 9.2 months) 8. Agents like pemetrexed, gefitinib, or erlotinib showed no objective response in neuroendocrine carcinomas 8.
Salvage therapy considerations:
- For recurrent disease after platinum-based therapy, irinotecan, platinum, or taxanes show relatively high objective responses 8
- Temozolomide-based regimens can be considered for second-line treatment 1, 2
Practical Implementation
For a newly diagnosed patient:
- Confirm poorly differentiated histology with immunohistochemistry for neuroendocrine markers (chromogranin A, synaptophysin, CD56)
- Stage completely to exclude distant metastases
- If resectable: proceed with surgery followed by adjuvant cisplatin/etoposide plus radiotherapy
- If unresectable: initiate cisplatin 100 mg/m² plus etoposide with concurrent or sequential radiotherapy
- For patients unfit for cisplatin: use carboplatin plus etoposide 1
Monitoring during treatment:
- Assess chromogranin A and NSE every 3-6 months if elevated at baseline 2
- CT imaging at 3-6 month intervals during active treatment 2
The evidence consistently demonstrates that neuroendocrine carcinomas are chemosensitive tumors responsive to platinum-etoposide combinations, with long-term survival possible in a minority of patients despite the aggressive nature of the disease 1.